Protective Effects of Pituitary Adenylate Cyclase-Activating Polypeptide and Vasoactive Intestinal Peptide Against Cognitive Decline in Neurodegenerative Diseases

Overview

Journal Front Cell Neurosci

Specialty Cell Biology

Date 2020 Aug 9

PMID 32765225

Citations 28

Authors

Irene Soles-Tarres

Nuria Cabezas-Llobet

David Vaudry

Xavier Xifro

Affiliations

Soon will be listed here.

Abstract

Cognitive impairment is one of the major symptoms in most neurodegenerative disorders such as Alzheimer's (AD), Parkinson (PD), and Huntington diseases (HD), affecting millions of people worldwide. Unfortunately, there is no treatment to cure or prevent the progression of those diseases. Cognitive impairment has been related to neuronal cell death and/or synaptic plasticity alteration in important brain regions, such as the cerebral cortex, substantia nigra, striatum, and hippocampus. Therefore, compounds that can act to protect the neuronal loss and/or to reestablish the synaptic activity are needed to prevent cognitive decline in neurodegenerative diseases. Pituitary adenylate cyclase-activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) are two highly related multifunctional neuropeptides widely distributed in the central nervous system (CNS). PACAP and VIP exert their action through two common receptors, VPAC1 and VPAC2, while PACAP has an additional specific receptor, PAC1. In this review article, we first presented evidence showing the therapeutic potential of PACAP and VIP to fight the cognitive decline observed in models of AD, PD, and HD. We also reviewed the main transduction pathways activated by PACAP and VIP receptors to reduce cognitive dysfunction. Furthermore, we identified the therapeutic targets of PACAP and VIP, and finally, we evaluated different novel synthetic PACAP and VIP analogs as promising pharmacological tools.

Citing Articles

Pituitary adenylyl cyclase-activating polypeptide modulates the stress response: the involvement of different brain areas and microglia.

Singh A, Shim P, Naeem S, Rahman S, Lutfy K Front Psychiatry. 2025; 15:1495598.

PMID: 39931196 PMC: 11807976. DOI: 10.3389/fpsyt.2024.1495598.

loss in zebrafish drives HPI axis hyperactivation via pathway and allostatic overload during later life.

Leggieri A, Judit Garcia-Gonzalez J, Garcia-Gonzalez J, Hosseinian S, Ashdown P, Anagianni S bioRxiv. 2024; .

PMID: 39464042 PMC: 11507754. DOI: 10.1101/2024.10.09.616976.

Technologies for the discovery of G protein-coupled receptor-targeting biologics.

Downey M, Peralta-Yahya P Curr Opin Biotechnol. 2024; 87:103138.

PMID: 38728825 PMC: 11250939. DOI: 10.1016/j.copbio.2024.103138.

Pleural mesothelioma from fluoro-edenite exposure: PACAP and PAC1 receptor. A preliminary report.

Lombardo C, Maugeri G, DAmico A, Broggi G, Caltabiano R, Filetti V Eur J Histochem. 2024; 68(2).

PMID: 38699968 PMC: 11110723. DOI: 10.4081/ejh.2024.3994.

Analysis of complement system and its related factors in Alzheimer's disease.

Zhu X, Tang B, Zhu M, Lu J, Lin H, Tang J BMC Neurol. 2023; 23(1):446.

PMID: 38114984 PMC: 10729410. DOI: 10.1186/s12883-023-03503-0.

References

Winner B, Kohl Z, Gage F . Neurodegenerative disease and adult neurogenesis. Eur J Neurosci. 2011; 33(6):1139-51. DOI: 10.1111/j.1460-9568.2011.07613.x. View

Vaudry D, Basille M, Anouar Y, Fournier A, Vaudry H, Gonzalez B . The neurotrophic activity of PACAP on rat cerebellar granule cells is associated with activation of the protein kinase A pathway and c-fos gene expression. Ann N Y Acad Sci. 1999; 865:92-9. DOI: 10.1111/j.1749-6632.1998.tb11167.x. View

Brenneman D, Gozes I . A femtomolar-acting neuroprotective peptide. J Clin Invest. 1996; 97(10):2299-307. PMC: 507310. DOI: 10.1172/JCI118672. View

Zhou C, Kikuyama S, Shibanuma M, Hirabayashi T, Nakajo S, Arimura A . Cellular distribution of the splice variants of the receptor for pituitary adenylate cyclase-activating polypeptide (PAC(1)-R) in the rat brain by in situ RT-PCR. Brain Res Mol Brain Res. 2000; 75(1):150-8. DOI: 10.1016/s0169-328x(99)00300-9. View

Ciranna L, Cavallaro S . Opposing effects by pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal peptide on hippocampal synaptic transmission. Exp Neurol. 2004; 184(2):778-84. DOI: 10.1016/S0014-4886(03)00300-5. View

Ramos-Alvarez I, Mantey S, Nakamura T, Nuche-Berenguer B, Moreno P, Moody T . A structure-function study of PACAP using conformationally restricted analogs: Identification of PAC1 receptor-selective PACAP agonists. Peptides. 2015; 66:26-42. PMC: 4420714. DOI: 10.1016/j.peptides.2015.01.009. View

Falluel-Morel A, Aubert N, Vaudry D, Basille M, Fontaine M, Fournier A . Opposite regulation of the mitochondrial apoptotic pathway by C2-ceramide and PACAP through a MAP-kinase-dependent mechanism in cerebellar granule cells. J Neurochem. 2004; 91(5):1231-43. DOI: 10.1111/j.1471-4159.2004.02810.x. View

Stranahan A . Physiological variability in brain-derived neurotrophic factor expression predicts dendritic spine density in the mouse dentate gyrus. Neurosci Lett. 2011; 495(1):60-2. PMC: 3081893. DOI: 10.1016/j.neulet.2011.03.037. View

PELLEGRI G, Magistretti P, Martin J . VIP and PACAP potentiate the action of glutamate on BDNF expression in mouse cortical neurones. Eur J Neurosci. 1998; 10(1):272-80. DOI: 10.1046/j.1460-9568.1998.00052.x. View

10.

Masuo Y, Matsumoto Y, Tokito F, Tsuda M, Fujino M . Effects of vasoactive intestinal polypeptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP) on the spontaneous release of acetylcholine from the rat hippocampus by brain microdialysis. Brain Res. 1993; 611(2):207-15. DOI: 10.1016/0006-8993(93)90504-g. View

11.

Dickson L, Finlayson K . VPAC and PAC receptors: From ligands to function. Pharmacol Ther. 2008; 121(3):294-316. DOI: 10.1016/j.pharmthera.2008.11.006. View

12.

Harmar A, Fahrenkrug J, Gozes I, Laburthe M, May V, Pisegna J . Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1. Br J Pharmacol. 2012; 166(1):4-17. PMC: 3415633. DOI: 10.1111/j.1476-5381.2012.01871.x. View

13.

Gonzalez B, Basille M, Vaudry D, Fournier A, Vaudry H . Pituitary adenylate cyclase-activating polypeptide promotes cell survival and neurite outgrowth in rat cerebellar neuroblasts. Neuroscience. 1997; 78(2):419-30. DOI: 10.1016/s0306-4522(96)00617-3. View

14.

Reglodi D, Renaud J, Tamas A, Tizabi Y, Socias S, Del-Bel E . Novel tactics for neuroprotection in Parkinson's disease: Role of antibiotics, polyphenols and neuropeptides. Prog Neurobiol. 2015; 155:120-148. DOI: 10.1016/j.pneurobio.2015.10.004. View

15.

Yu R, Zeng Z, Guo X, Zhang H, Liu X, Ding Y . The TAT peptide endows PACAP with an enhanced ability to traverse bio-barriers. Neurosci Lett. 2012; 527(1):1-5. DOI: 10.1016/j.neulet.2012.08.005. View

16.

Onoue S, Endo K, Ohshima K, Yajima T, Kashimoto K . The neuropeptide PACAP attenuates beta-amyloid (1-42)-induced toxicity in PC12 cells. Peptides. 2002; 23(8):1471-8. DOI: 10.1016/s0196-9781(02)00085-2. View

17.

Nomura M, Ueta Y, Serino R, Kabashima N, Shibuya I, Yamashita H . PACAP type I receptor gene expression in the paraventricular and supraoptic nuclei of rats. Neuroreport. 1996; 8(1):67-70. DOI: 10.1097/00001756-199612200-00014. View

18.

Usdin T, Bonner T, Mezey E . Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions. Endocrinology. 1994; 135(6):2662-80. DOI: 10.1210/endo.135.6.7988457. View

19.

Han P, Tang Z, Yin J, Maalouf M, Beach T, Reiman E . Pituitary adenylate cyclase-activating polypeptide protects against β-amyloid toxicity. Neurobiol Aging. 2014; 35(9):2064-71. DOI: 10.1016/j.neurobiolaging.2014.03.022. View

20.

Maasz G, Zrinyi Z, Reglodi D, Petrovics D, Rivnyak A, Kiss T . Pituitary adenylate cyclase-activating polypeptide (PACAP) has a neuroprotective function in dopamine-based neurodegeneration in rat and snail parkinsonian models. Dis Model Mech. 2017; 10(2):127-139. PMC: 5312006. DOI: 10.1242/dmm.027185. View